Detalhe da pesquisa
1.
Clozapine Rechallenge After Neutropenia or Leucopenia.
J Clin Psychopharmacol
; 36(4): 377-80, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27232877
2.
[Risk minimization evolution of agranulocytosis caused by the administration of pharmaceutical products containing Clozapine in Argentina]. / Evolución de la minimización del riesgo de producir agranulocitosis por la administración de especialidades medicinales que contienen clozapina en Argentina.
Vertex
; 22(96): 94-7, 2011.
Artigo
em Espanhol
| MEDLINE | ID: mdl-21977603
3.
[Analysis of advertising on neurological drugs received during the medical consultation]. / Análisis de publicidades sobre medicamentos neurológicos recibidos durante la consulta médica.
Medicina (B Aires)
; 81(4): 559-564, 2021.
Artigo
em Espanhol
| MEDLINE | ID: mdl-34453797
4.
[Hospital pharmacovigilance in Buenos Aires]. / Farmacovigilancia hospitalaria en Buenos Aires.
Medicina (B Aires)
; 74(1): 84-5, 2014.
Artigo
em Espanhol
| MEDLINE | ID: mdl-24561854
5.
A Critical View of "On TB Vaccines, Patients' Demands, and Modern Printed Media in Times of Biomedical Uncertainties: Buenos Aires, 1920-1950".
J Bioeth Inq
; 15(1): 19-22, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29256022
6.
[Issues regarding the legal regulation of drugs in Argentina]. / Consideraciones sobre la regulación de medicamentos vigente en la Argentina.
Vertex
; 17(67): 220-3, 2006.
Artigo
em Espanhol
| MEDLINE | ID: mdl-16847481
7.
Análisis de publicidades sobre medicamentos neurológicos recibidos durante la consulta médica / Analysis of advertising on neurological drugs received during the medical consultation
Medicina (B.Aires)
; 81(4): 559-564, ago. 2021. graf
Artigo
em Espanhol
| LILACS | ID: biblio-1346507
8.
Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012).
Int Clin Psychopharmacol
; 30(2): 109-14, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25486383
9.
[Declaration of Helsinki: its vicissitudes during the last five years]. / Declaración de Helsinki. Sus vicisitudes en los últimos cinco años.
Medicina (B Aires)
; 62(4): 365-70, 2002.
Artigo
em Espanhol
| MEDLINE | ID: mdl-12325498
10.
Uso de oseltamivir durante la pandemia de gripe a (H1N1): análisis de las reacciones adversas reportadas al sistema nacional de farmacovigilancia de ANMAT / Use of oseltamivir during influenza A (H1N1) pandemic: analysis of adverse reactions reported to the ANMAT national pharmacovigilance system
Rev. argent. salud publica
; 1(4): 20-25, sept. 2010. tab
Artigo
em Espanhol
| LILACS | ID: lil-597389
11.
Farmacovigilancia hospitalaria en Buenos Aires
Medicina (B.Aires)
; 74(1): 84-85, ene.-feb. 2014.
Artigo
em Espanhol
| LILACS | ID: lil-708567
12.
[Inadequate use of antibiotics and education]. / Uso inapropiado de antibióticos y educación.
Arch Argent Pediatr
; 107(2): 191-2, 2009 Apr.
Artigo
em Espanhol
| MEDLINE | ID: mdl-19455763
13.
Transferring the financial risks of pharmaceutical benefits from a large health care provider in Argentina to a consortium of pharmaceutical companies.
Rev Panam Salud Publica
; 13(4): 203-13, 2003 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12804149
14.
Declaracion de Helsinki: sus vicisitudes en los ultimos cinco años / Declaration of Helsinki: its vicissitudes during the last five years
Medicina (B.Aires)
; 62(4): 365-370, 2002.
Artigo
em Espanhol
| LILACS | ID: lil-317331
15.
Transferring the financial risks of pharmaceutical benefits from a large health care provider in Argentina to a consortium of pharmaceutical companies
Rev. panam. salud pública
; 13(4): 203-213, abr. 2003. tab
Artigo
em Inglês
| LILACS | ID: lil-346113
16.
Transferring the financial risks of pharmaceutical benefits from a large health care provider in Argentina to a consortium of pharmaceutical companies
Revista Panamericana de Salud Pública (OPS) = Pan American Journal of Public Health (PAHO)
; 13(4): 203-213, 2003.
Artigo
em Inglês
| PAHO | ID: pah-244097
17.
Transferring the financial risks of pharmaceutical benefits from a large health care provider in Argentina to a consortium of pharmaceutical companies
Rev Panam Salud Publica
; 13(4),abr. 2003 tab
Artigo
| PAHOIRIS | ID: phr-8387